Valuation: Orthocell Limited

Market Cap 157M 107M 96.45M 89.03M 80.58M 152M 10.03B 1.07B 425M 5.36B 400M 392M 17.06B P/E 2027 *
-11.5x
P/E 2028 * -28.7x
Enterprise Value 128M 87.42M 79.05M 72.97M 66.05M 125M 8.22B 876M 348M 4.39B 328M 321M 13.98B EV / Sales 2027 *
8.05x
EV / Sales 2028 * 4.33x
Free-Float
83.04%
Yield 2027 *
-
Yield 2028 * -
1 day-2.61%
1 week-2.61%
Current month+1.82%
1 month-17.65%
3 months-29.11%
6 months-32.53%
Current year-48.39%
1 week 0.56
Extreme 0.555
0.6
1 month 0.49
Extreme 0.49
0.69
Current year 0.49
Extreme 0.49
1.16
1 year 0.49
Extreme 0.49
1.16
3 years 0.35
Extreme 0.35
1.79
5 years 0.3
Extreme 0.3
1.79
10 years 0.1
Extreme 0.105
1.79
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 21/03/2006
Chief Executive Officer 60 21/03/2006
Director of Finance/CFO - 01/08/2025
Director TitleAgeSince
Director/Board Member 60 21/03/2006
Director/Board Member 60 08/03/2023
Chairman - 01/06/2023
Date Insider Type Main position Quantity % Market Cap. Importance
7/20/26 A Buy

Chairman

15,430 0.0057%
7/17/26 A Buy 11,573 0.0043%
7/17/26 A Buy

Director

16,603 0.0061%
Change 5-day change 1-year change 3-year change Capi.($)
-2.61%-2.61%-49.09%+34.94% 107M
-1.87%-5.59%-16.74%+14.13% 186B
-0.61%-3.67%+5.41%+42.88% 124B
-2.01%-6.77%-14.96%+14.17% 119B
+0.61%-6.60%-43.42%+2.40% 91.43B
-0.14%+2.86%-3.86%+76.84% 66.67B
+0.55%+1.01%+12.28%-8.07% 58.76B
-0.65%+4.07%-2.18%+62.81% 54.99B
-0.68%+6.83%-1.64%+55.26% 49.93B
-5.17%+0.55% - - 35.13B
Average -1.26%-1.42%-12.69%+32.82% 79B
Weighted average by Cap. -1.06%-3.37%-10.58%+27.59%

Financials

2027 *2028 *
Net sales 15.95M 10.86M 9.82M 9.07M 8.21M 15.49M 1.02B 109M 43.25M 546M 40.76M 39.9M 1.74B 30.65M 20.87M 18.87M 17.42M 15.77M 29.76M 1.96B 209M 83.1M 1.05B 78.33M 76.66M 3.34B
Net income -14.4M -9.81M -8.87M -8.19M -7.41M -13.98M -922M -98.25M -39.04M -493M -36.8M -36.02M -1.57B -7.75M -5.28M -4.77M -4.41M -3.99M -7.52M -496M -52.88M -21.01M -265M -19.81M -19.38M -844M
Net Debt -28.25M -19.24M -17.4M -16.06M -14.53M -27.43M -1.81B -193M -76.6M -967M -72.2M -70.66M -3.08B -23.8M -16.21M -14.66M -13.53M -12.25M -23.11M -1.52B -162M -64.53M -815M -60.83M -59.53M -2.59B
Projected Income Statement - Annual - Orthocell Limited
Logo Orthocell Limited
Orthocell Limited is an Australia-based regenerative medicine company. The Company is focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Its portfolio of products includes Striate+, Remplir, and OrthoACI. Striate+ is an acellular resorbable collagen membrane used for guided bone and tissue regeneration in dental applications. Remplir is a collagen-based nerve wrap designed to support nerve repair surgery in peripheral nerve repair. OrthoACI, or Autologous Chondrocyte Implantation, offers treatment for symptomatic defects of the articulating cartilage of the joints. OrthoACI uses the patient’s own healthy cartilage cells called chondrocytes to assist the regeneration of damaged cartilage. The Company is engaged in the development of its tendon cell therapy in the United States. Its autologous tendon therapy is an advanced injectable cellular therapy for the treatment of chronic tendon injuries.
Employees
-
Date Price Change Volume
13/11/26 A$0.5600 -2.61% 347,019
12/11/26 A$0.5750 -0.86% 214,161
11/11/26 A$0.5800 -2.52% 461,955
10/11/26 A$0.5950 +0.85% 430,387
09/11/26 A$0.5900 +2.61% 456,062
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.5750AUD
Average target price
0.9000AUD
Spread / Average Target
+56.52%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Orthocell Limited